Indications
Treatment of major depressive disorder; Treatment of diabetic peripheral neuropathic pain; Treatment of generalised anxiety disorder; Xeristar is indicated in adults.
Composition
- Active substance
- duloxetine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nodetrip (previously Xeristar)
- Active substance
- duloxetine
- ATC code
- N06AX21
- Group
- Nervous system
- Therapeutic area
- Anxiety Disorders, Depressive Disorder, Major, Diabetic Neuropathies
- Marketing authorisation holder
- Esteve Pharmaceuticals, S.A.
- Status
- Withdrawn